| Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (NCT03289780) | Biodesix, Inc. | 2016-04-04 |
| Detection Cell Free DNA in Lung Cancer Patients (NCT02738593) | Sun Yat-sen University | 2016-04-01 |
| Immune Boost In Non-Small Cell Lung Cancer (NCT02319408) | University Hospital Heidelberg | 2016-04-01 |
| First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001 (NCT02896231) | Beijing Pearl Biotechnology Limited Liability Company | 2016-04-01 |
| uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung (NCT02755675) | Rigshospitalet, Denmark | 2016-04-01 |
| Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure (NCT02725918) | Guangdong Association of Clinical Trials | 2016-04-01 |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) (NCT02638090) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-22 |
| Alvopem® (Pemetrexed) Safety Assessment (NCT04843007) | NanoAlvand | 2016-03-15 |
| Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC (NCT02591615) | Alliance Foundation Trials, LLC. | 2016-03-01 |
| Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (NCT02648724) | Symphogen A/S | 2016-03-01 |
| High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases (NCT02726568) | Betta Pharmaceuticals Co., Ltd. | 2016-03-01 |
| Paclitaxel Detection in NSCLC Treated With TC Regimen (NCT02737709) | Sun Yat-sen University | 2016-03-01 |
| The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer (NCT02733107) | Third Military Medical University | 2016-03-01 |
| Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550) | Centaurus Biopharma Co., Ltd. | 2016-03-01 |
| A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer (NCT02734524) | Southwest Hospital, China | 2016-03-01 |
| A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC (NCT02630186) | Clovis Oncology, Inc. | 2016-02-24 |
| A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies (NCT02572687) | Eli Lilly and Company | 2016-02-19 |
| Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NCT02659059) | Bristol-Myers Squibb | 2016-02-15 |
| OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (NCT02654587) | OSE Immunotherapeutics | 2016-02-12 |
| Noninvasive vs. Invasive Lung Evaluation (NCT03615443) | Guardant Health, Inc. | 2016-02-12 |
| Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (NCT02679963) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-02-05 |
| Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease (NCT02469701) | howard safran | 2016-02-01 |
| Suction on Post-Operative Chest Tubes (NCT02911259) | Rigshospitalet, Denmark | 2016-02-01 |
| Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria (NCT02619929) | Pierre Fabre Pharma GmbH | 2016-02-01 |
| Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma (NCT02710565) | Mid and South Essex NHS Foundation Trust | 2016-02-01 |
| D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) (NCT02651441) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2016-02-01 |
| Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies (NCT02702921) | Ethicon Endo-Surgery | 2016-02-01 |
| Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer (NCT02673814) | Peregrine Pharmaceuticals | 2016-02-01 |
| MPDL3280A With Chemoradiation for Lung Cancer (NCT02525757) | M.D. Anderson Cancer Center | 2016-01-26 |
| ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02523469) | Medical University of South Carolina | 2016-01-08 |
| Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NCT02014545) | Wake Forest University Health Sciences | 2016-01-01 |
| Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy (NCT02360761) | Peking University People's Hospital | 2016-01-01 |
| Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT (NCT02617186) | St. Joseph's Healthcare Hamilton | 2016-01-01 |
| The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase (NCT02755337) | Dr. Soetomo General Hospital | 2016-01-01 |
| Abscopal Effect for Metastatic Non-small Cell Lung Cancer. (NCT02542930) | Zhejiang Provincial People's Hospital | 2016-01-01 |
| EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment (NCT02644889) | GenoSaber | 2016-01-01 |
| Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (NCT02470065) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-01-01 |
| Uncommon EGFR AZD9291 (NCT03424759) | Samsung Medical Center | 2016-01-01 |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer (NCT02460367) | NewLink Genetics Corporation | 2016-01-01 |
| Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC (NCT02669719) | Shanghai Chest Hospital | 2016-01-01 |
| Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method) (NCT02661009) | GenoSaber | 2016-01-01 |
| Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer (NCT01951469) | Sun Yat-sen University | 2016-01-01 |
| Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC (NCT02730897) | University Hospital, Gasthuisberg | 2016-01-01 |
| A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC (NCT02852083) | University Hospital Regensburg | 2016-01-01 |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) (NCT02584634) | Pfizer | 2015-12-18 |
| Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (NCT02613507) | Bristol-Myers Squibb | 2015-12-11 |
| ImmuniCell® in Patients With Advanced Cancers (NCT02459067) | TC Biopharm | 2015-12-01 |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (NCT02646020) | Sun Yat-sen University | 2015-12-01 |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (NCT02537561) | Washington University School of Medicine | 2015-12-01 |
| Evaluate EGFR Mutation Status and Impact Factors in North China (NCT02620657) | ying cheng | 2015-12-01 |
| Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer (NCT02950337) | Loyola University | 2015-12-01 |
| Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (NCT02504489) | BeyondSpring Pharmaceuticals Inc. | 2015-12-01 |
| Time Trends in Waiting Times of NSCLC Patients. (NCT01946490) | Maastricht Radiation Oncology | 2015-12-01 |
| Multiple-portal VATS Versus Uniportal VATS Lobectomy for Non-small Cell Lung Cancer (NCT02462356) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2015-12-01 |
| A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02574078) | Bristol-Myers Squibb | 2015-11-23 |
| Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia (NCT02839629) | Bristol-Myers Squibb | 2015-11-23 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC (NCT02473133) | Centre Henri Becquerel | 2015-11-12 |
| Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (NCT02504372) | Merck Sharp & Dohme LLC | 2015-11-06 |
| Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (NCT02604342) | Hoffmann-La Roche | 2015-11-03 |
| Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer (NCT02841228) | Hunan Province Tumor Hospital | 2015-11-01 |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC (NCT02592577) | Adaptimmune | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (NCT02433574) | Juravinski Cancer Center | 2015-11-01 |
| Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases (NCT02616393) | Kadmon Corporation, LLC | 2015-11-01 |
| Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor (NCT02562963) | Minghui Zhang | 2015-11-01 |
| Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (NCT02486718) | Hoffmann-La Roche | 2015-10-31 |
| Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET (NCT02544633) | Mirati Therapeutics Inc. | 2015-10-01 |
| A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC (NCT02463994) | University of Michigan Rogel Cancer Center | 2015-10-01 |
| Liquid Biopsy for Detection of Driver Mutation in NSCLC (NCT02778854) | Chinese PLA General Hospital | 2015-10-01 |
| Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor (NCT02587689) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2015-10-01 |
| Real-world Data of Nivolumab in Pre-treated NSCLC (NCT04713462) | Hellenic Cooperative Oncology Group | 2015-10-01 |
| Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer (NCT02643407) | Guangdong Association of Clinical Trials | 2015-10-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer (NCT02580708) | Clovis Oncology, Inc. | 2015-09-30 |
| A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification (NCT02468661) | Novartis Pharmaceuticals | 2015-09-23 |
| Genomic Landscape of Ceritinib (NCT02554591) | Washington University School of Medicine | 2015-09-16 |
| SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer (NCT02562027) | Washington University School of Medicine | 2015-09-11 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) (NCT02495233) | Astellas Pharma Global Development, Inc. | 2015-09-08 |
| An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). (NCT02321046) | AstraZeneca | 2015-09-02 |
| Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC (NCT02577627) | Optimata Ltd. | 2015-09-01 |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC (NCT03780010) | Tracon Pharmaceuticals Inc. | 2015-09-01 |
| Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations (NCT02277457) | University of Michigan Rogel Cancer Center | 2015-09-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients (NCT02708667) | Sun Yat-sen University | 2015-09-01 |
| Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NCT02485652) | Hanmi Pharmaceutical Company Limited | 2015-08-31 |
| Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) (NCT02437136) | Syndax Pharmaceuticals | 2015-08-26 |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (NCT02450903) | Novartis Pharmaceuticals | 2015-08-21 |
| An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (NCT02477826) | Bristol-Myers Squibb | 2015-08-05 |
| Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer (NCT02577341) | Sun Yat-sen University | 2015-08-01 |
| Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer (NCT03006575) | Sun Yat-sen University | 2015-08-01 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib (NCT02538627) | Merrimack Pharmaceuticals | 2015-08-01 |
| Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer (NCT02573506) | Sun Yat-sen University | 2015-08-01 |
| EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC (NCT02714010) | Sun Yat-sen University | 2015-08-01 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (NCT02475213) | MacroGenics | 2015-07-01 |
| Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (NCT02492568) | The Netherlands Cancer Institute | 2015-07-01 |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (NCT02468024) | University of Texas Southwestern Medical Center | 2015-07-01 |